These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24934165)

  • 1. Modulation of Doxorubicin mediated growth inhibition of hepatocellular carcinoma cells by platelet lysates.
    Refolo MG; D'Alessandro R; Lippolis C; Messa C; Carella N; Cavallini A; Carr BI
    Anticancer Agents Med Chem; 2014; 14(8):1154-60. PubMed ID: 24934165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
    D'Alessandro R; Refolo MG; Lippolis C; Giannuzzi G; Carella N; Messa C; Cavallini A; Carr BI
    BMC Cancer; 2014 May; 14():351. PubMed ID: 24885890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
    Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
    J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The activation of p38 and JNK by ROS, contribute to OLO-2-mediated intrinsic apoptosis in human hepatocellular carcinoma cells.
    Zhang Z; Zhang C; Ding Y; Zhao Q; Yang L; Ling J; Liu L; Ji H; Zhang Y
    Food Chem Toxicol; 2014 Jan; 63():38-47. PubMed ID: 24211866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
    D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1237-1245. PubMed ID: 25907508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1.
    Lippolis C; Refolo MG; D'Alessandro R; Carella N; Messa C; Cavallini A; Carr BI
    J Exp Clin Cancer Res; 2015 Sep; 34(1):90. PubMed ID: 26329608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
    Manov I; Pollak Y; Broneshter R; Iancu TC
    FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
    D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
    Cell Oncol (Dordr); 2018 Jun; 41(3):283-296. PubMed ID: 29470830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Juglone induces apoptosis and autophagy via modulation of mitogen-activated protein kinase pathways in human hepatocellular carcinoma cells.
    Wang P; Gao C; Wang W; Yao LP; Zhang J; Zhang SD; Li J; Fang SH; Fu YJ
    Food Chem Toxicol; 2018 Jun; 116(Pt B):40-50. PubMed ID: 29627502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent.
    You ML; Chen YJ; Chong QY; Wu MM; Pandey V; Chen RM; Liu L; Ma L; Wu ZS; Zhu T; Lobie PE
    Oncotarget; 2017 Jun; 8(24):39323-39344. PubMed ID: 28445151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery.
    Carr BI; Cavallini A; Lippolis C; D'Alessandro R; Messa C; Refolo MG; Tafaro A
    J Cell Physiol; 2013 Feb; 228(2):292-7. PubMed ID: 22777740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma.
    Huynh H; Chow PK; Soo KC
    Mol Cancer Ther; 2007 Sep; 6(9):2468-76. PubMed ID: 17876044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eucalrobusone C suppresses cell proliferation and induces ROS-dependent mitochondrial apoptosis via the p38 MAPK pathway in hepatocellular carcinoma cells.
    Jian KL; Zhang C; Shang ZC; Yang L; Kong LY
    Phytomedicine; 2017 Feb; 25():71-82. PubMed ID: 28190473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of ERK1/2 and p38 MAP kinase in doxorubicin-induced uPA expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells.
    Niiya M; Niiya K; Shibakura M; Asaumi N; Yoshida C; Shinagawa K; Teshima T; Ishimaru F; Ikeda K; Tanimoto M
    Oncology; 2004; 67(3-4):310-9. PubMed ID: 15557793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase.
    Feng YM; Feng CW; Chen SY; Hsieh HY; Chen YH; Hsu CD
    BMC Cancer; 2015 Mar; 15():134. PubMed ID: 25886177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
    Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T
    Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment].
    Zhang YX; Kong CZ
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):271-5. PubMed ID: 18361842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.